



Cell-free DNA from cerebrospinal fluid can be used to detect the *EGFR* mutation status of lung adenocarcinoma patients with central nervous system metastasis

Yang Liu^{1#}, Sen Yang^{2,3#}, Jiuzhou Zhao⁴, Zhen He², Jie Ma⁴, Yongjun Guo⁴, Wei Wang⁵, Akihiko Yoshizawa⁶, Arselja Prelaj^{7,8}, Marcello Tiseo⁹, Nicola Normanno¹⁰, Paul E. Van Schil¹¹, Qiming Wang², Xiaopeng Yang³

¹Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; ²Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; ³Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ⁴Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Key Laboratory of Molecular Pathology, Zhengzhou, China; ⁵Henan Medical Association, Zhengzhou, China; ⁶Department of Diagnostic Pathology, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan; ⁷Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ⁸Department of Electronics, Information, and Bioengineering, Polytechnic University of Milan, Milan, Italy; ⁹Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy; ¹⁰Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori—IRCCS—“Fondazione G. Pascale”, Naples, Italy; ¹¹Department of Thoracic and Vascular Surgery, University Hospital of Antwerp, Edegem, Belgium

Contributions: (I) Conception and design: Q Wang, X Yang; (II) Administrative support: W Wang, Y Guo; (III) Provision of study materials or patients: Z He, Y Liu, J Ma; (IV) Collection and assembly of data: S Yang, J Zhao; (V) Data analysis and interpretation: S Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Qiming Wang. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Email: qimingwang1006@126.com; Xiaopeng Yang. Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Email: yaxipe39@126.com.

Background: EGFR tyrosine kinase inhibitors (TKIs) have revolutionized the therapeutic approach for *EGFR* mutated patients. However, acquired resistance to EGFR-TKI therapy is unavoidable. Repeat biopsy cannot be used, and peripheral blood detection shows a low positive rate in cases of brain-only disease progression.

Methods: Droplet digital polymerase chain reaction (PCR) (ddPCR) was performed on the plasma and cerebrospinal fluid (CSF) samples of 79 lung adenocarcinoma (LUAD) patients with *EGFR* mutations and central nervous system (CNS) metastasis. The differences in the *EGFR* mutation status between the paired plasma and CSF samples were assessed, and the role of CSF testing as a predictor of overall survival was evaluated.

Results: The CSF of patients with neurological symptoms, EGFR-TKI treatment, or leptomeningeal metastasis (LM) had a significantly higher positive rate of *EGFR* mutation compared to the plasma samples ($P=0.001$, $P=0.035$, $P=0.019$, respectively). Moreover, *EGFR* mutation status in CSF was consistent with neurological symptoms and LM ($\kappa=0.455$, $P<0.001$; $\kappa=0.508$, $P<0.001$; respectively). For the patients with brain metastasis, *EGFR* mutation-positive rate in CSF samples was lower than that in plasma samples (28.3% vs. 64.2%, $P<0.001$), while the patients with LM had the opposite result (84.6% vs. 38.5%, $P=0.004$). Moreover, patients with *EGFR* mutation in their CSF experienced worse survival [hazard ratio (HR) =2.93, 95% confidence interval (CI): 1.45–5.92; $P=0.003$, $P_{\text{adjust}}<0.0001$].

Conclusions: The *EGFR* mutation status of CSF was different from that of plasma and is correlated with patient prognosis. CSF could be helpful in detecting the *EGFR* mutation status of patients, particularly in cases of LM.

Keywords: Non-small cell lung cancer (NSCLC); leptomeningeal metastasis (LM); liquid biopsy; cerebrospinal fluid (CSF); *EGFR* mutation

Submitted Jul 30, 2020. Accepted for publication Feb 20, 2021.

doi: 10.21037/tlcr-21-62

View this article at: <http://dx.doi.org/10.21037/tlcr-21-62>

Introduction

Lung cancer, with the highest rate of cancer-related mortality worldwide (1), is among the most common human malignancies. Non-small cell lung cancer (NSCLC) accounts for approximately 90% of all global lung cancer cases (2). Epidermal growth factor receptor (EGFR)-activating mutations, such as L858R and exon 19 deletion (E19Del), have been found in approximately 10–15% of NSCLC patients in Western countries and 40–55% of patients in Asian countries (3). NSCLC patients with *EGFR* mutations have a significantly high risk of developing metastasis of the central nervous system (CNS), including leptomeningeal metastasis (LM) and brain metastasis (BM), which is associated with poor prognosis and compromised quality of life (4). The combined incidence of BM and LM in NSCLC patients is more than 50% (5-7). For NSCLC patients with BM and LM who receive EGFR tyrosine kinase inhibitor (TKI) therapy, the median overall survival (OS) is 10.3–16.2 months (8) and 4.5–11 months (9,10), respectively, which is markedly shorter than that for patients without CNS metastasis. EGFR-TKIs have ushered in a new era of targeted therapy in NSCLC and have dramatically improved the progression-free survival (PFS) of patients who harbor EGFR-activating mutations (11-17). Nevertheless, acquired resistance to EGFR-TKI therapy is inevitable. Therefore, rebiopsy is needed to detect secondary resistance mechanisms in order to develop a new treatment strategy.

With its many advantages, the detection of tumor-specific genetic alterations in body fluids has become a supplement to or even a replacement for established tissue-based tumor diagnostics, and thus has garnered considerable attention in academic research and the medical testing industry (18). Moreover, circulating tumor DNA (ctDNA) has been widely used to detect *EGFR* mutations status in patients who develop resistance to targeted therapy (19). ctDNA derives from tumors or circulating tumor cells (CTCs), and constitutes a fraction of the cell-free DNA (cfDNA) that is extracted from body fluids, which also contain DNA derived

from non-transformed cells (20). ctDNA has been shown to be capable of accurately reflecting tumor-specific genomic alterations and can be used to monitor tumor progression, response to treatment, and relapse (21). Therefore, ctDNA testing might be an ideal detection tool in cancer patients. Moreover, cerebrospinal fluid (CSF) has shown utility as a liquid biopsy medium for the gene expression profiling of NSCLC patients with LM, contributing to more sensitive and effective diagnoses (22). However, due to the blood-brain barrier (BBB), the *EGFR* mutation status in CSF is not consistent with that in plasma, and controversy still surrounds which of the two is a better indicator of *EGFR* alterations in patients with CNS metastasis (23,24). Several studies have reported tumor-associated alterations being detectable in the CSF ctDNA of patients with various primary or metastatic brain tumors, while little ctDNA was found in the plasma of these patients (25-28). These findings indicate that CSF has a stronger capability to recapitulate the genomic profile of CNS tumors/metastatic sites than does plasma.

In the present study, we performed droplet digital polymerase chain reaction (ddPCR) on paired plasma and CSF samples from 79 lung adenocarcinoma (LUAD) patients with *EGFR* mutations and CNS metastasis. Through comparing the *EGFR* mutation status of the plasma and CSF samples, we aimed to determine the ability of CSF compared to plasma in detecting *EGFR* mutation in patients with LUAD and CNS metastasis.

We present the following article in accordance with the MDAR reporting checklist (available at <http://dx.doi.org/10.21037/tlcr-21-62>).

Methods

Patients

This study included 79 LUAD patients with CNS metastasis harboring *EGFR* mutations in tumor tissue (L858R or E19Del). All patients were diagnosed at Henan Cancer Hospital between 2012 and 2018. The last follow-up took

Table 1 Characteristics of 79 patients with brain metastases and leptomeningeal metastases

Characteristics	Brain metastases			Leptomeningeal metastases		
	EGFR-TKI naïve	EGFR-TKI treated	Total	EGFR-TKI naïve naïvenainaïvenaive	EGFR-TKI treated	Total
Total	24	29	53	5	21	26
Sex						
Male	10	17	27	1	11	12
Female	14	12	26	4	10	14
Age						
<60 years	11	17	28	3	13	16
≥60 years	13	12	25	2	8	10
Smoking status						
No	18	20	38	4	15	19
Yes	6	9	15	1	6	7
Neurological symptoms						
No	11	12	23	0	3	3
Yes	13	17	30	5	18	23
Chemotherapy						
No	19	6	25	4	6	10
Yes	5	23	28	1	15	16
Local CNS RT						
No	23	23	46	5	18	23
Yes	1	6	7	0	3	3
Number of metastases ^a						
Single	8	1	9	1	4	5
Multiple	16	28	44	4	15	19

^a, two patients with leptomeningeal metastases and EGFR-TKI treatment were negative by MRI but positive by ThinPrep cytologic test. TKI, tyrosine kinase inhibitors; CNS, central nervous system; RT, radiotherapy.

place on April 20, 2019, and six patients were lost to follow-up. CNS metastasis was confirmed in all patients by brain magnetic resonance imaging (MRI) and ThinPrep cytologic testing (TCT), which were performed according to standard procedures by experienced radiologists and pathologists. Patient clinical data including sex, age, smoking status, chemotherapy, local CNS radiotherapy, and history of EGFR-TKI treatment were collected from the electronic medical records of Henan Cancer Hospital (*Table 1*).

All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). This study was conducted

in accordance with the ethical guidelines of the United States' common rule, and the protocol was approved by the Research Ethics Committee of Henan Cancer Hospital. All patients signed informed consent forms.

Sample processing and DNA extraction

After the CNS metastases were diagnosed, CSF (10 mL) and peripheral blood (15 mL) were collected by lumbar puncture and blood sampling respectively (*Figure 1*). The collected samples were preserved in EDTA tubes (SANLI) for the isolation of cfDNA. The DNA isolation procedure




Figure 1 The workflow of the present study. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.

was performed within 2 h after sample collection. To collect plasma, the peripheral blood samples were subjected to centrifugation. Then, the plasma and CSF were first centrifuged at 2,000 $\times g$ for 10 min at 4 °C and again at 16,000 $\times g$ for 10 min at 4 °C. The QIAamp Circulating Nucleic Acid Kit (#55114, QIAGEN, Hilden, Germany) was used to capture cfDNA according to the manufacturer's instructions. The quality and concentration of the DNA were assessed using a Qubit dsDNA HS assay (#1204008450, Life Technologies, Carlsbad, CA, USA). DNA was also isolated from the CSF sediment for the ddPCR test. The extracted DNA was stored at -20 °C for later analysis.

ddPCR test

A QX200 digital PCR system (Bio-Rad Laboratories, Hercules, CA, USA) was used to conduct the ddPCR assays (29). For exon 19 deletions, p.L858R and p.T790M were detected using a human-EGFR ddPCR detection kit (#CB240005, YuanQi) according to the manufacturer's instructions. The PCR program was as follows: 95 °C for 10 min; 40 cycles of 94 °C for 15 s and 58 °C for 60 s; 98 °C for 10 min; and 4 °C for 5 min. The reaction volume was set to 40 μ L. The reaction temperature was changed at a rate of less than 2 °C/s. After thermal cycling, the amplified samples were loaded into a BioRad reader (#771BR24449, Bio-Rad Laboratories) for quantification. These experiments were performed according to the protocols of the Mutation Detection Best Practices Guidelines supplied by Bio-Rad Laboratories (Figure 1).

Statistical analysis

Paired χ^2 (McNemar's test) and kappa tests were utilized to compare the clinical characteristics and *EGFR* mutation status in the plasma and CSF samples from the enrolled patients, and to compare the different subgroups divided according to their clinical data. Wilcoxon signed-rank test was used to evaluate the difference in *EGFR* mutation abundance between paired CSF and plasma samples. The patients' survival probabilities associated with the *EGFR* mutation status of CSF were analyzed by Kaplan-Meier curves and adjusted with clinical variables. Receiver operating characteristic (ROC) curve and time-dependent area under the curve (AUC) analyses were used to evaluate the accuracy of the predictive model by integrating the effects of both clinical variables and the *EGFR* mutation status of CSF on patient survival. All statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA), with the level of statistical significance set at a P value <0.05, unless otherwise indicated.

Results

Patient characteristics

The 79 patients enrolled in this study were diagnosed with advanced LUAD and confirmed to harbor sensitizing *EGFR* mutations, with 25 of these patients being treatment naïve. As shown in Table 1, 53 patients were diagnosed with BM and 26 with LM. Furthermore, 50 had a history of EGFR-TKI treatment, 44 patients had received chemotherapy, and

10 had received local CNS radiotherapy. The median age of the patients was 56 (range, 29–76) years, and 39 patients were male, including 22 who had history of smoking; none of the female patients smoked. Most patients (53 of 79) had neurological symptoms, including dizziness and headache, and most (63 of 77) had more than one metastatic lesion of the CNS.

EGFR gene mutation status in CSF supernatant and sediment

First, to determine whether supernatant or sediment could better represent CSF, McNemar's test and kappa tests were used to compare the *EGFR* mutation status between paired samples of CSF supernatant and sediment from the 79 patients. As shown in [Table S1](#), no statistically significant differences were observed in the positive rate of *EGFR* mutations between the supernatant and sediment of CSF (43.0% *vs.* 34.2%, $P=0.092$). Moreover, the two samples were generally consistent (kappa =0.656; range, 0.40–0.75; $P<0.001$). However, a difference was observed in the abundance (mutated alleles/mutated alleles and wild type alleles) of positive supernatant and sediment samples, with the abundance in the supernatant higher than that in the sediment [median (quartile): 33.00% (23.00–49.30%) and 5.30% (2.20–15.00%), respectively].

EGFR gene mutation status and clinical characteristics

To determine if there was any correlation between *EGFR* mutation and clinical features, we compared the *EGFR* mutation status of the patients' plasma and CSF samples with various clinical characteristics. As shown in [Table 2](#), a higher frequency of *EGFR* mutation was observed in the plasma samples of never smokers, patients with multiple CNS metastases, patients treated with radiotherapy, and patients without LM (61.4% *vs.* 40.9%, $P=0.002$; 58.0% *vs.* 40.0%, $P<0.001$; 58.7% *vs.* 50.0%, $P=0.001$; and 64.2% *vs.* 38.5%, $P=0.015$; respectively). No statistically significant differences in *EGFR* mutation status were found for other variables including sex, age, neurological symptoms, chemotherapy treatment history, or EGFT-TKI treatment history ($P>0.05$). All these characteristics showed poor consistency with *EGFR* mutation status in plasma (kappa <0.4).

For the CSF samples, patients with neurological symptoms (50.9% *vs.* 36.4%, $P=0.032$), no history of radiotherapy (47.8% *vs.* 40.0%, $P<0.001$), presence of

multiple CNS metastases (including LM) (47.6% *vs.* 35.7%, $P<0.001$), and an EGFT-TKI treatment history (54.0% *vs.* 34.5%, $P=0.035$), along with non-smokers (64.2% *vs.* 11.5%, $P=0.001$) and LM patients (84.6% *vs.* 28.3%, $P=0.019$), had a higher risk of being *EGFR* mutation-positive. The other variables had no significant correlation with the *EGFR* mutation status of CSF. Moreover, neurological symptoms and LM showed general consistency with *EGFR* mutation status in CSF (kappa =0.455, $P<0.001$; kappa =0.508, $P<0.001$; respectively).

EGFR gene mutation status in CSF and plasma samples in different subgroups

To ascertain the difference between CSF and plasma in reflecting the *EGFR* mutations of patients, the *EGFR* mutation status between paired CSF and plasma samples from all patients was compared. As shown in [Table S2](#), there was not a statistically significant difference in the positive rate of *EGFR* mutations between the paired CSF and plasma samples ($P=0.360$; kappa =-0.081, $P=0.466$). However, the number of positive CSF samples was significantly higher than that of plasma samples [33.00% (16.80–49.30%) and 2.05% (0.67–14.75%), respectively].

Next, the 79 patients were divided into different subgroups according to their clinical characteristics. The *EGFR* mutation status of the paired CSF and plasma samples from patients in different subgroups was compared. In the BM patient group, the positive rate of *EGFR* mutations was notably lower in the CSF samples than in plasma samples (28.3% *vs.* 64.2%, $P<0.001$; kappa =0.093, $P=0.381$), while the opposite result was observed in the LM patient group (84.6% *vs.* 38.5%, $P=0.004$; kappa =-0.061, $P=0.606$) ([Tables S3,S4](#)). No significant difference between the *EGFR* mutation-positive rate of the CSF and plasma samples was observed in other subgroups, including patients with neurological symptoms ($P=0.697$), without EGFR-TKI treatment history ($P=0.202$), with EGFR-TKI treatment history ($P=0.777$), with *EGFR* E19Del ($P=0.821$) and *EGFR* 21 exon L858R mutation ($P=0.320$) ([Tables S5-S10](#)).

Different subtypes of EGFR gene mutations in CSF and plasma

Although the positive rates of E19Del and p.L858R mutation were not significantly different between the CSF and plasma samples from any of the patients, as shown in [Tables S9,S10](#), respectively, we questioned whether the

Table 2 Comparison of *EGFR* mutation status of the patients with different characteristics from plasma and CSF samples of 79 patients

Characteristics	Mutation status in plasma		P	Kappa test		Mutation status in CSF		P	Kappa test	
	Negative (%)	Positive (%)		Value	P	Negative (%)	Positive (%)		Value	P
Total	35 (44.3)	44 (55.7)	–	–	–	42 (53.2)	37 (46.8)	–	–	–
Sex			0.636	–0.014	0.900			0.736	0.115	0.307
Male	17 (43.6)	22 (56.4)				23 (59.0)	16 (41.0)			
Female	18 (45.0)	22 (55.0)				19 (47.5)	21 (52.5)			
Age			0.211	–0.025	0.822			0.880	–0.122	0.278
<60 years	19 (43.2)	25 (56.8)				21 (47.7)	23 (52.3)			
≥60 years	16 (45.7)	19 (54.3)				21 (60.0)	14 (40.0)			
Smoking status			0.002	–0.157	0.100			0.032	–0.120	0.247
No	22 (38.6)	35 (61.4)				28 (49.1)	29 (50.9)			
Yes	13 (59.1)	9 (40.9)				14 (63.6)	8 (36.4)			
Neurological symptoms			0.233	–0.185	0.090			0.001	0.455	<0.001
No	8 (30.8)	18 (69.2)				23 (88.5)	3 (11.5)			
Yes	27 (50.9)	26 (49.1)				19 (35.8)	34 (64.2)			
Chemotherapy			1.000	–0.129	0.253			0.311	0.120	0.278
No	13 (37.1)	22 (62.9)				21 (60.0)	14 (40.0)			
Yes	22 (50.0)	22 (50.0)				21 (47.7)	23 (52.3)			
Local CNS RT			<0.001	–0.073	0.285			<0.001	–0.036	0.643
No	29 (42.0)	40 (58.0)				36 (52.2)	33 (47.8)			
Yes	6 (60.0)	4 (40.0)				6 (60.0)	4 (40.0)			
Number of metastases ^a			0.001	0.057	0.550			<0.001	0.067	0.418
Single	7 (50.0)	7 (50.0)				9 (64.3)	5 (35.7)			
Multiple	26 (41.3)	37 (58.7)				33 (52.4)	30 (47.6)			
EGFR-TKIs			0.451	–0.149	0.181			0.035	0.178	0.094
Naïve	10 (34.5)	19 (65.5)				19 (65.5)	10 (34.5)			
Treated	25 (50.0)	25 (50.0)				23 (46.0)	27 (54.0)			
LM			0.015	–0.218	0.031			0.019	0.508	<0.001
No	19 (35.8)	34 (64.2)				38 (71.7)	15 (28.3)			
Yes	16 (61.5)	10 (38.5)				4 (15.4)	22 (84.6)			

^a, two patients with leptomeningeal metastases and EGFR-TKI treatment were negative by MRI but positive by ThinPrep cytologic test. CSF, cerebrospinal fluid; TKI, tyrosine kinase inhibitors; CNS, central nervous system; RT, radiotherapy; LM, leptomeningeal metastasis.

EGFR mutation status differed between the plasma and CSF samples of patients with BM or LM. Here, three mutations were analyzed: p.L858R in exon 21, E19Dels, and p.T790M in exon 20). As shown in *Table 3*, the positive rates of L858R, E19Dels, and p.T790M mutations in the

CSF samples from BM patients were all lower than those in the plasma samples. However, for patients with LM, the positive rates of p.L858R and E19Dels in the CSF samples were both higher than those in the plasma samples, while T790M showed no significant difference.

Table 3 The *EGFR* mutation types in plasma and cerebrospinal fluid among patients with CNS metastasis

Characteristics	Plasma			Cerebrospinal fluid		
	L858R	19del	T790M	L858R	19del	T790M
Brain metastases						
EGFR-TKI naïve	7/10 (70.0%)	11/14 (78.6%)	1/1 (100.0%)	1/10 (10.0%)	4/14 (28.6%)	0/1 (00.0%)
EGFR-TKI treated ^a	7/15 (46.7%)	10/15 (66.7%)	4/7 (57.1%)	4/15 (26.7%)	7/15 (46.7%)	0/7 (00.0%)
Total	14/25 (56.0%)	21/29 (72.4%)	5/8 (62.5%)	5/25 (20.0%)	11/29 (37.9%)	0/8 (00.0%)
Leptomeningeal metastases						
EGFR-TKI naïve ^b	0/3 (00.0%)	1/3 (33.3%)	0	3/3 (100.0%)	3/3 (100.0%)	0
EGFR-TKI treated	5/14 (35.7.0%)	4/7 (57.1%)	4/9 (44.4%)	11/14 (78.6%)	6/7 (85.7%)	4/9 (44.4%)
Total	5/17 (29.4%)	5/10 (50.0%)	4/9 (44.4%)	14/17 (82.4%)	9/10 (90.0%)	4/9 (44.4%)

^a, 1 patient had both L858R and 19del *EGFR* mutation; ^b, 1 patient had both L858R and 19del *EGFR* mutation. TKI, tyrosine kinase inhibitors; CNS, central nervous system.

EGFR gene mutation abundance in CSF and plasma

Since ddPCR allows for the quantitative detection of ctDNA, a Wilcoxon signed-rank test was employed to assess the differences in *EGFR* mutation abundance in paired CSF and plasma samples in positive patients. The median *EGFR* mutation abundances in CSF and plasma samples were 33.50% and 1.75%, respectively, with a median difference of 29.14%. The Wilcoxon signed-rank test results ($Z = -3.509$ and $P < 0.001$) indicated that the *EGFR* mutation abundance in CSF was significantly higher than that in plasma (Table S11). The comparison of the median *EGFR* mutation abundance in the paired CSF and plasma samples from patients with BM and LM is displayed in Figure 2, including three specific mutations: p.L858R in exon 21, E19dels, and exon 20 p.T790M. Overall, in LM patients, the abundance of E19dels, p.L858R, and p.T790M in CSF was higher than that in plasma, while in BM patients, the abundance of p.T790M in CSF was lower than that in plasma.

EGFR gene mutation status and patient survival

Finally, we investigated if there was any correlation between *EGFR* mutation status and OS. Complete follow-up data of 73 of 79 patients were available for analysis. The patients' plasma and CSF samples were separately analyzed using Kaplan-Meier survival analysis, with adjustment for available covariations including sex, age, and smoking status. As shown in Figure 3A, the analysis of plasma samples indicated that the difference in median survival time between patients with and without *EGFR* mutations

was not significant [19.7 vs. 14.4 months, hazard ratio (HR) = 1.24, 95%, confidence interval (CI): 0.63–2.45; $P = 0.531$, $P_{\text{adjust}} = 0.819$]. However, patients with *EGFR* mutation in their CSF had significantly worse survival than patients without *EGFR* mutation in their CSF (HR = 2.93, 95% CI: 1.45–5.92; $P = 0.003$, $P_{\text{adjust}} < 0.0001$) (Figure 3B).

Then, we assessed the role of the *EGFR* mutation status of CSF in predicting the OS of patients by using time-dependent AUC and ROC curves at the 12th month (or 1-year survival). Compared with the models for age, sex, and smoking status, the time-dependent AUC plotted for additional *EGFR* mutation status in CSF was improved. The AUCs were improved from 70.81–82.40% ($P = 0.066$) for 1-year survival (Figure 3C,D).

Discussion

In this study, ddPCR was used to quantitatively detect *EGFR* mutation status in paired plasma and CSF samples from LUAD patients with CNS metastasis. The results showed that for patients with LM, the abundance of *EGFR* mutation in CSF *EGFR* mutation-positive samples was higher than that in plasma, and the *EGFR* mutation status of CSF was significantly different from that of plasma. Further survival analysis indicated that patients with *EGFR* mutation in their CSF had worse survival than patients without *EGFR* mutation in their CSF. These results suggest that for patients with LM, *EGFR* mutations can be detected more effectively in CSF than in plasma samples. This presents a potentially effective alternative or supplement for




Figure 2 Distribution of different *EGFR* mutation sites in paired plasma and CSF. In leptomeningeal metastasis patients, the abundance of E19del, L858R, and T790M in CSF was higher than that in plasma, while the abundance of T790M in CSF was lower than that in plasma. BM, brain metastasis; LM, leptomeningeal metastasis; CSF, cerebrospinal fluid.

plasma liquid biopsy for the detection of *EGFR* mutations in patients with CNS metastasis. Furthermore, the *EGFR* mutation status of CSF could serve as a biomarker for predicting the OS of patients with CNS metastasis.

Next-generation sequencing (NGS) can be used to monitor LM development and guide precision medicine (4). However, NGS has not been widely used in clinical practice due to its high cost and technological complexity. ddPCR was used as our liquid biopsy method over SuperARMS and NGS due to its higher sensitivity and specificity (the sensitivity is lower than 0.1%), which suggests that more patients would benefit from this method.

Most patients harboring *EGFR* mutations develop CNS metastasis (30); however, treatment with *EGFR*-TKIs eventually results in acquired resistance. The acquired resistance mechanisms can be either *EGFR*-dependent or *EGFR*-independent, such as is in T790M or *MET* amplification, respectively. The latter mechanism seems to be the most frequent, appearing in nearly 50% of LM cases (31). Therefore, the treatment strategy selected depends on the patient's *EGFR* mutation status at a particular time. Liquid biopsy facilitates the detection of the *EGFR* mutation status of patients who are unwilling to undergo tissue aspiration

biopsy or from whom a tumor tissue sample cannot be obtained (32). cfDNA is a short fragment (usually 130–180 base pairs) double-stranded DNA that is present in plasma and other body fluids (33–36). It is thought to originate mainly from apoptotic or necrotic cell death, although active release mechanisms have also been investigated (37,38). In cancer patients, cfDNA is derived from both non-malignant and malignant cells, with the percentage of ctDNA originating from cancer cells ranging from 3% to 93% (38). Moreover, cancer patients are frequently observed to have increased levels of cfDNA in their plasma, and under certain circumstances, increased cfDNA is considered to be an adverse prognostic factor (39). Increased levels of cfDNA might also be attributable to impaired renal clearance function or production of white plasma cells (WBC) (40,41). In contrast, ctDNA in CSF is quite stable, meaning it has the potential to facilitate and supplement the diagnosis of LM due to the low sensitivity of CSF cytology, especially in cases that cannot be detected by traditional cytopathological analysis (26).

We included both *EGFR*-TKI-naïve and *EGFR*-TKI-treated patients in this study. In the *EGFR*-TKI-naïve patients, the *EGFR* mutation-positive rate in plasma was




Figure 3 Kaplan-Meier survival curve according to *EGFR* mutation status in plasma and CSF. The difference of median survival time between patients with and without *EGFR* mutations was not significant (A). The patients with *EGFR* mutations in their CSF had significantly worse survival than patients without *EGFR* mutation in their CSF (B). Compared with the model for age, sex, and smoking status, the model with addition of *EGFR* mutation status in CSF showed improvement of time-dependent AUC plot (C,D). CSF, cerebrospinal fluid; AUC, area under the curve.

65.5%, which is generally consistent with previous reports. However, a downward trend in the *EGFR* mutation-positive rate was observed in the plasma of patients with a history of EGFR-TKI therapy. This can be explained by the fact that few *EGFR* mutation-positive NSCLC cells survive in extracranial circulations after EGFR-TKI treatment. Nevertheless, the *EGFR* mutation-positive rate in the CSF samples displayed an opposite trend. The reason for this might be that leptomeninges and CSF could become a safe harbor for protecting *EGFR* mutation-positive NSCLC cells during EGFR-TKI therapy because of the BBB.

In this study, although no statistically significant difference or consistency was observed in the positive rate of *EGFR* mutations in CSF and plasma samples when the entire cohort was analyzed, for patients with neurological

symptoms, LM, or those with an EGFR-TKI treatment history, *EGFR* mutation-positive rates in CSF were higher than those in plasma. Moreover, in the patients with LM, the mutation abundance in CSF was significantly higher than that in the plasma samples. This might be due to ctDNA only constituting a small fraction of the cfDNA in plasma arising from the large amount of DNA produced by normal cells, while few normal cells exist in CSF, which results in a notably higher proportion of ctDNA. These results suggest that for patients with EGFR-TKI resistance and CNS metastasis, testing CSF-derived cfDNA might be more effective than testing plasma. Furthermore, our analysis indicated that patients with *EGFR* mutations in their CSF had worse survival, meaning that meningeal metastases might have occurred in these patients, which

would dramatically increase the risk of death, although this was not diagnosed by TCT or MRI.

The mechanisms of cfDNA release are poorly understood, and their predictive role and relationship to tumor burden are controversial and still being investigated (42,43). We assessed the correlation between the OS of patients and the cfDNA status in both plasma and CSF samples, and found that the cfDNA status in CSF was negatively correlated with patient survival. This result suggests that *EGFR* mutation status or cfDNA in the CSF might be a promising predictor for OS in LUAD patients with CNS metastasis. Previous studies demonstrated a correlation between plasma levels of ctDNA and survival (21,22). The lack of correlation found in this study could be due to the fact that plasma is not adequate to predict patients' survival for patients with CNS metastases.

As far as we know, the present study is the largest to explore *EGFR* mutation status in the CSF of LUAD patients with CNS metastasis, and has yielded new insight into the comparison of *EGFR* mutation status in paired CSF and plasma samples with ddPCR. Nevertheless, this study has some limitations. First, the sample size of 79 patients was not large enough, which might have resulted in the introduction of biases, including low statistical power, higher false discovery rate, and low reproducibility. Secondly, only L858R, E19del, and T790M mutations can be detected by ddPCR, which limited the exploration of the possible molecular mechanism of BM. Finally, this study was performed in a Chinese population and, therefore, may not be representative of other ethnic groups.

In conclusion, we found that the *EGFR* mutation status in CSF was different from that in plasma, and CSF could more effectively reflect the *EGFR* mutation status of LUAD patients with CNS metastasis. Our results indicate that the detection of *EGFR* mutation status in CSF could serve as an efficient alternative or supplement to plasma testing. Furthermore, for patients with acquired resistance to *EGFR*-TKIs, liquid biopsy of CSF would be an excellent tool for detecting *EGFR* mutation status to inform future treatment decision-making.

Acknowledgments

Marcello Tiseo is currently supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) under Investigator Grant (IG) No. IG2017-20074.

Funding: This study was supported by the Henan Province Health and Youth Subject Leader Training Project

{{[2020]60}; the Leading Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (YXKC2020009); the Zhongyuan Qianren Jihua (ZYQR201912118); the Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer {{[2021]10}; the Henan Medical Key Laboratory of Refractory lung cancer {{[2020]27}; the Henan Refractory Lung Cancer Drug Treatment Engineering Technology Research Center {{[2020]4}; the 51282 Project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents {{[2016]32}; the Huilan Charity Fund (HL-HS2020-129); Major public welfare projects in Henan Province (201300310400).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <http://dx.doi.org/10.21037/tlcr-21-62>

Data Sharing Statement: Available at <http://dx.doi.org/10.21037/tlcr-21-62>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tlcr-21-62>). MT has received speakers' and consultants' fees from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT received institutional research grants from Astra-Zeneca and Boehringer Ingelheim, during the conduct of the study; PEVS is an external expert of National Cancer Institute (France), MSD, AstraZeneca (institutional fees only), during the conduct of the study; NN received speakers' and consultants' fee from MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, MERCK, ThermoFisher, Boehringer Ingelheim, Astrazeneca, Sanofi, Eli Lilly, Nicola Normanno received institutional research grants from MERCK, Sysmex, ThermoFisher, QIAGEN, Roche, Astrazeneca, Biocartis, Illumina, during the conduct of the study. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised

in 2013). This study was conducted in accordance with the ethical guidelines of the United States' common rule, and the protocol was approved by the Research Ethics Committee of Henan Cancer Hospital. All the patients in the present study have signed informed consent.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30.
2. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. *Lancet* 2011;378:1727-40.
3. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Res* 2004;64:8919-23.
4. Fan Y, Zhu X, Xu Y, et al. Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer. *Clin Cancer Res* 2018;24:209-16.
5. Palma JA, Fernandez-Torron R, Esteve-Belloc P, et al. Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. *Clin Neurol Neurosurg* 2013;115:19-25.
6. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. *Nat Clin Pract Oncol* 2006;3:50-7; quiz 1 p following 57.
7. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. *Lung Cancer* 2015;88:108-11.
8. Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. *Onco Targets Ther* 2014;7:2075-84.
9. Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. *Lung Cancer* 2012;77:134-9.
10. Liao BC, Lee JH, Lin CC, et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. *J Thorac Oncol* 2015;10:1754-61.
11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735-42.
12. Wu YL, Zhou C, Liang CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Ann Oncol* 2015;26:1883-9.
13. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239-46.
14. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
15. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8.
16. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8.
17. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 2015;16:141-51.
18. Lehmann U, Bartels S. Liquid biopsy in tumor diagnostics: Applications, perspectives, and limitations of the "cancer liquidome". *Pathologie* 2019;40:250-5.
19. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol* 2013;10:472-84.
20. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nat Rev Cancer* 2017;17:223-38.

21. Johann DJ Jr, Steliga M, Shin JJ, et al. Liquid biopsy and its role in an advanced clinical trial for lung cancer. *Exp Biol Med (Maywood)* 2018;243:262-71.
22. Jiang BY, Li YS, Guo WB, et al. Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. *Clin Cancer Res* 2017;23:5480-8.
23. Huang R, Xu X, Li D, et al. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases. *Target Oncol* 2019;14:343-50.
24. Zhao J, Ye X, Xu Y, et al. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. *Cancer Chemother Pharmacol* 2016;78:1305-10.
25. Pentsova EI, Shah RH, Tang J, et al. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. *J Clin Oncol* 2016;34:2404-15.
26. De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun* 2015;6:8839.
27. Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. *Clin Chem* 2015;61:514-22.
28. Ying S, Ke H, Ding Y, et al. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases. *Cancer Biol Ther* 2019;20:562-70.
29. Yang K, Li J, Zhao J, et al. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients. *Anal Chem* 2018;90:11203-9.
30. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. *Lancet Oncol* 2018;19:e43-55.
31. Li YS, Jiang BY, Yang JJ, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. *Ann Oncol* 2018;29:945-52.
32. Kim E, Feldman R, Wistuba, II. Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer. *Clin Lung Cancer* 2018;19:105-14.
33. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res* 1977;37:646-50.
34. Casadio V, Salvi S, Martignano F, et al. Cell-Free DNA Integrity Analysis in Urine Samples. *J Vis Exp* 2017;(119):55049.
35. Chan LY, Leung TN, Chan KC, et al. Serial analysis of fetal DNA concentrations in maternal plasma in late pregnancy. *Clin Chem* 2003;49:678-80.
36. Chan MH, Chow KM, Chan AT, et al. Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions. *Clin Chem* 2003;49:740-5.
37. Stroun M, Anker P. Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon. *Cell Mol Biol (Noisy-le-grand)* 2005;51:767-74.
38. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res* 2001;61:1659-65.
39. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. *J Clin Oncol* 2004;22:4157-64.
40. McGuire AL, Urosevic N, Chan DT, et al. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. *PPAR Res* 2014;2014:643189.
41. Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. *Clin Chem* 2002;48:421-7.
42. Bath IS, Mitra A, Manier S, et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. *Ann Oncol* 2017;28:468-77.
43. Li BT, Drilon A, Johnson ML, et al. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. *Ann Oncol* 2016;27:154-9.

(English Language Editor: J. Gray)

Cite this article as: Liu Y, Yang S, Zhao J, He Z, Ma J, Guo Y, Wang W, Yoshizawa A, Prelaj A, Tiseo M, Normanno N, Van Schil PE, Wang Q, Yang X. Cell-free DNA from cerebrospinal fluid can be used to detect the *EGFR* mutation status of lung adenocarcinoma patients with central nervous system metastasis. *Transl Lung Cancer Res* 2021;10(2):914-925. doi: 10.21037/tlcr-21-62

Supplementary

Table S1 The comparison of *EGFR* mutation status in the supernatant and sediment of the CSF of all 79 patients

	Supernatant		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
Sediment				0.092	0.656	<0.001
Positive	24	3	27			
Negative	10	42	52			
Total	34	45	79			

The abundance median/quartile of the positive samples of supernatant and sediment was 33.00% (23.00–49.30%) and 5.30% (2.20–15.00%), respectively. CSF, cerebrospinal fluid.

Table S2 The comparison of *EGFR* mutation status in CSF and plasma in all 79 patients

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.360	–0.081	0.466
Positive	19	18	37			
Negative	25	17	42			
Total	44	35	79			

The abundance median/quartile of the positive samples of CSF and plasma was 33.00% (16.80–49.30%) and 2.05% (0.67–14.75%), respectively. CSF, cerebrospinal fluid.

Table S3 The comparison of *EGFR* mutation status in the CSF and plasma of 53 BM patients

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				<0.001	0.093	0.381
Positive	11	4	15			
Negative	23	15	38			
Total	34	19	53			

The abundance median/quartile of the positive samples of CSF and plasma was 33.00% (11.00–46.70%) and 2.60% (0.90–19.40%), respectively. BM, brain metastasis; CSF, cerebrospinal fluid.

Table S4 The comparison of *EGFR* mutation status in the CSF and plasma of 26 LM patients

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.004	–0.061	0.606
Positive	8	14	22			
Negative	2	2	4			
Total	10	16	26			

The abundance median/quartile of the positive samples of CSF and plasma was 31.80% (16.80–55.00%) and 1.27% (0.37–5.08%), respectively. LM, leptomeningeal metastasis; CSF, cerebrospinal fluid.

Table S5 The comparison of *EGFR* mutation status in the CSF and plasma of 26 patients without neurological symptoms

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				NA	NA	NA
Positive	3	0	3			
Negative	15	8	23			
Total	18	8	26			

The abundance median/quartile of the positive samples of CSF and plasma was 40.00% and 2.20% (0.90–9.90%), respectively. CSF, cerebrospinal fluid.

Table S6 The comparison of *EGFR* mutation status in the CSF and plasma of 53 patients with neurological symptoms

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.185	-0.051	0.697
Positive	16	18	34			
Negative	10	9	19			
Total	26	27	53			

The abundance median/quartile of the positive samples of CSF and plasma was 32.10% (15.00–49.30%) and 2.00% (0.63–19.50%), respectively. CSF, cerebrospinal fluid.

Table S7 The comparison of *EGFR* mutation status in the CSF and plasma of 29 EGFR-TKI-naïve patients

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.064	-0.195	0.202
Positive	5	5	10			
Negative	14	5	19			
Total	19	10	29			

The abundance median/quartile of the positive samples of CSF and plasma was 4.90% (3.70–33.80%) and 2.80% (0.60–20.50%), respectively. CSF, cerebrospinal fluid; TKI, tyrosine kinase inhibitor.

Table S8 The comparison of *EGFR* mutation status in the CSF and plasma of 50 EGFR-TKI-treated patients

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.839	0.040	0.777
Positive	14	13	27			
Negative	11	12	23			
Total	25	25	50			

The abundance median/quartile of the positive samples of CSF and plasma was 33.50% (26.65–52.15%) and 2.00% (0.70–10.60%), respectively. CSF, cerebrospinal fluid; TKI, tyrosine kinase inhibitor.

Table S9 The comparison of *EGFR* mutation status in the CSF and plasma of 39 patients with *EGFR* exon 19 deletion*

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				0.263	-0.034	0.821
Positive	13	7	20			
Negative	13	6	19			
Total	26	13	39			

The abundance median/quartile of the positive samples of CSF and plasma was 33.00% (16.40–43.85%) and 1.95% (0.70–9.90%), respectively. *, two patients had both L858R and E19Del *EGFR* mutation. CSF, cerebrospinal fluid.

Table S10 The comparison of *EGFR* mutation status in CSF and plasma in 42 patients with *EGFR* exon 21 L858R mutation*

	Plasma		Total	McNemar's test	Kappa test	
	Positive	Negative		P	Value	P
CSF				1.000	-0.153	0.320
Positive	7	12	19			
Negative	12	11	23			
Total	19	23	42			

The abundance median/quartile of the positive samples of CSF and plasma was 29.60% (15.00–49.30%) and 2.40% (0.57–10.60%), respectively. *, two patients had both L858R and E19Del *EGFR* mutation. CSF, cerebrospinal fluid.

Table S11 The comparison of *EGFR* mutation abundance in CSF and plasma

<i>EGFR</i> mutation abundance	Distribution	Median	Z	P
CSF	0.90–94.60%	33.50%	-3.509	<0.001
Plasma	0.16–81.60%	1.75%		

CSF, cerebrospinal fluid.